https://orcid.org/0000-0003-0560-4447
-
Views
-
Cite
Cite
Willis K Samson, Gina L C Yosten, Renin Finds a New Target, Endocrinology, Volume 166, Issue 5, May 2025, bqaf061, https://doi.org/10.1210/endocr/bqaf061
Close - Share Icon Share
Extract
While training with Charles Nicoll at UC Berkley, Carmen Clapp published a paper in Endocrinology (1) that would jump-start more than 35 years of discovery-based research, which now has led to great promise for the potential development of novel therapeutics for the treatment of numerous vasoproliferative diseases including, but not limited to, retinopathy of prematurity (ROP). They advanced the work of Indraneel Mittra, who had reported the action of a cleaved form of prolactin (PRL) to exert mitogenic actions like those of native PRL (2). Fast forward to the 1990s, when Clapp extended the work on cleavage products of native PRL to demonstrate the production and action of those products on endothelial cells (3). Twenty years of insightful work was summarized by Clapp and colleagues in the Physiological Reviews manuscript that detailed the growing field of functional diversity in peptide hormones (4). Highlighted in that review was a large body of work detailing the action of vasoinhibin, a cleaved form of PRL, to affect vascular permeability and reactivity, actions not shared by the parent PRL form. This work and the discoveries of many others revealed the importance of posttranslational processing, in particular enzymatic modification, in the regulation of vascular physiology and pathophysiology.
